Imatinib Mesylate for Children With Dermatofibrosarcoma Protuberans (DFSP)

被引：40

作者：

Gooskens, Saskia L. M. ^{[1
]}

Oranje, Arnold P. ^{[2
]}

van Adrichem, Leon N. A. ^{[3
]}

de Waard-van der Spek, Flora B. ^{[2
]}

den Hollander, Jan C. ^{[4
]}

van de Ven, Cees P. ^{[5
]}

van den Heuvel-Eibrink, Marry M. ^{[1
]}

机构：

[1] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Oncol Hematol, NL-3015 GJ Rotterdam, Netherlands

[2] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Dermatol, NL-3015 GJ Rotterdam, Netherlands

[3] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Plast Surg, NL-3015 GJ Rotterdam, Netherlands

[4] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pathol, NL-3015 GJ Rotterdam, Netherlands

[5] Sophia Childrens Univ Hosp, Erasmus MC, Dept Pediat Surg, NL-3015 GJ Rotterdam, Netherlands

来源：

PEDIATRIC BLOOD & CANCER | 2010年 / 55卷 / 02期

关键词：

children; dermatofibrosarcoma protuberans; imatinib; treatment; CHILDHOOD; TUMORS;

D O I：

10.1002/pbc.22494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Dermatofibrosarcoma protuberans (DFSP) is a rare malignant soft tissue tumor in children. DFSP is characterized by a specific fusion of the platelet-derived growth factor beta (POGF beta) with the collagen type 1 alpha 1 (COL 1 alpha 1) gene which renders these tumors responsive to targeted therapy with tyrosine kinase inhibitors, such as imatinib mesylate, as is reported in adults. In the current report, we describe the first small pediatric DFSP series, in which response to imatinib mesylate contributed to successful treatment outcome. Pediatr Blood Cancer 2010;55:369-373. (C) 2010 Wiley-Liss, Inc.

引用

页码：369 / 373

页数：5

共 50 条

[21] The use of imatinib in the treatment of inoperable dermatofibrosarcoma protuberans in the area of the shoulder joint
Huszno, Joanna
Starzyczny-Slota, Danuta
Nowara, Elzbieta
PRZEGLAD DERMATOLOGICZNY, 2014, 101 (03): : 197 - 200
[22] DERMATOFIBROSARCOMA PROTUBERANS
Sanmartin, O.
Llombart, B.
Lopez-Guerrero, J. A.
Serra, C.
Requena, C.
Guillen, C.
ACTAS DERMO-SIFILIOGRAFICAS, 2007, 98 (02): : 77 - 87
[23] Using Imatinib as Neoadjuvant Therapy in Dermatofibrosarcoma Protuberans: Potential Pluses and Minuses
Johnson-Jahangir, Hillary
Sherman, William
Ratner, Desiree
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2010, 8 (08): : 881 - 885
[24] Tyrosine kinase inhibitors versus radiation therapy in unresectable dermatofibrosarcoma protuberans (DFSP): A narrative systematic review
Henry, Owen S.
Platoff, Rebecca
Cerniglia, Katherine S.
Batchu, Sai
Goodwin, Brandon J.
Sandilos, Georgianna
Adams, Amanda
Hong, Young K.
AMERICAN JOURNAL OF SURGERY, 2023, 225 (02) : 268 - 274
[25] Dermatofibrosarcoma protuberans
Ugurel, S.
HAUTARZT, 2008, 59 (11): : 933 - 939
[26] Dermatofibrosarcoma protuberans
Dimitropoulos, Vassilios A.
DERMATOLOGIC THERAPY, 2008, 21 (06) : 428 - 432
[27] Dermatofibrosarcoma Protuberans
Miller, Stanley J.
Alam, Murad
Andersen, James S.
Berg, Daniel
Bichakjian, Christopher K.
Bowen, Glen M.
Cheney, Richard T.
Frank Glass, L.
Grekin, Roy C.
Ho, Alan L.
Kessinger, Anne
Liegeois, Nanette
Lydiatt, Daniel D.
Michalski, Jeff
Morrison, William H.
Nehal, Kishwer S.
Nelson, Kelly C.
Nghiem, Paul
Olencki, Thomas
Perlis, Clifford S.
Shaha, Ashok R.
Tuli, Malika
Urist, Marshall M.
Wang, Linda C.
Zic, John A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (03): : 312 - 318
[28] Dermatofibrosarcoma Protuberans
Serra-Guillen, C.
Llombart, B.
Sanmartin, O.
ACTAS DERMO-SIFILIOGRAFICAS, 2012, 103 (09): : 762 - 777
[29] Abscopal Effect of Radiotherapy in Imatinib-resistant Dermatofibrosarcoma Protuberans
Agyeman, Mervin B.
Vanderpuye, Verna D.
Yarney, Joel
CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (01)
[30] Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer
Handolias, Despina
McArtbur, Grant A.
FUTURE ONCOLOGY, 2008, 4 (02) : 211 - 217

← 1 2 3 4 5 →